theory clinical_30_2
imports Main

begin

typedecl entity
typedecl event

consts
  Mutation :: "entity ⇒ bool"
  Activating :: "entity ⇒ bool"
  CTNNB1 :: "entity ⇒ bool"
  Proliferation :: "entity ⇒ bool"
  Cell :: "entity ⇒ bool"
  Promote :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  βCatenin :: "entity ⇒ bool"
  Via :: "event ⇒ entity ⇒ bool"
  Inhibit :: "event ⇒ bool"
  Reduce :: "event ⇒ bool"
  Stop :: "event ⇒ bool"
  Cause :: "event ⇒ entity ⇒ bool"
  Through :: "event ⇒ event ⇒ bool"
  Consider :: "event ⇒ bool"
  Treatment :: "event ⇒ bool"
  Effective :: "event ⇒ bool"
  Treat :: "event ⇒ bool"
  CTTNB1 :: "entity ⇒ bool"
  CTNNB :: "entity ⇒ bool"  (* Added missing constant definition *)

(* Explanation 1: Activating mutations of CTNNB1 promote proliferation of cells via β-catenin. *)
axiomatization where
  explanation_1: "∃x y z e. Mutation x ∧ Activating x ∧ CTNNB1 x ∧ Proliferation y ∧ Cell y ∧ Promote e ∧ Agent e x ∧ Patient e y ∧ βCatenin z ∧ Via e z"

(* Explanation 2: Inhibiting β-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB. *)
axiomatization where
  explanation_2: "∃x y z e1 e2. Inhibit e1 ∧ βCatenin x ∧ Proliferation y ∧ Cell y ∧ (Reduce e2 ∨ Stop e2) ∧ Agent e2 x ∧ Patient e2 y ∧ Cause e2 z ∧ Mutation z ∧ Activating z ∧ CTNNB z"

(* Explanation 3: Reducing or stopping the proliferation of cells through inhibiting β-catenin can be considered a treatment for patients with activating CTNNB1 mutations. *)
axiomatization where
  explanation_3: "∃x y z w e1 e2 e3. (Reduce e1 ∨ Stop e1) ∧ Proliferation x ∧ Cell x ∧ Inhibit e2 ∧ βCatenin y ∧ Through e1 e2 ∧ Consider e3 ∧ Treatment e3 ∧ Patient e3 z ∧ Mutation z ∧ Activating z ∧ CTNNB1 z"

theorem hypothesis:
  assumes asm: "βCatenin x ∧ Mutation y ∧ Activating y ∧ CTTNB1 y"
  (* Hypothesis: Inhibiting β-catenin may be effective in treating patients with activating CTTNB1 mutations. *)
  shows "∃x y e1 e2. Inhibit e1 ∧ βCatenin x ∧ Patient e1 x ∧ Effective e2 ∧ Treat e2 ∧ Patient e2 y ∧ Mutation y ∧ Activating y ∧ CTTNB1 y"
proof -
  (* From the known information, we have βCatenin x, Mutation y, Activating y, and CTTNB1 y. *)
  from asm have "βCatenin x ∧ Mutation y ∧ Activating y ∧ CTTNB1 y" by meson
  (* Explanation 2 provides that inhibiting β-catenin can reduce or stop the proliferation of cells caused by activating mutations of CTNNB. *)
  (* This implies that inhibiting β-catenin can prevent the proliferation of cells. *)
  (* Explanation 3 states that reducing or stopping the proliferation of cells through inhibiting β-catenin can be considered a treatment for patients with activating CTNNB1 mutations. *)
  (* Therefore, inhibiting β-catenin is effective in treating patients with activating CTNNB1 mutations. *)
  then have "∃e1 e2. Inhibit e1 ∧ βCatenin x ∧ Patient e1 x ∧ Effective e2 ∧ Treat e2 ∧ Patient e2 y ∧ Mutation y ∧ Activating y ∧ CTTNB1 y" sledgehammer
  then show ?thesis <ATP>
qed

end
